-
Isis Pharmaceuticals Finally Breaks Out
Wednesday, August 27, 2014 - 12:30pm | 320Read More...The markets appear back in rally mode over the last couple weeks. With that, the biotech industry has performed very well. The iShares Biotechnology ETF (NASDAQ: IBB) hit a new all-time high Tuesday and is continuing higher. Many individual biotech stocks made big moves, as well. One in...
-
Barron's Recap: The Changing World Of MLPs
Sunday, August 11, 2013 - 1:00pm | 831Read More...This weekend in Barron's online: a roundtable discussion of the changing landscape of master limited partnerships, and the prospects for the Washington Post, BNP Paribas, HD Supply, Isis Pharmaceuticals and Redbox. Cover Story "MLP Boom or Bust?" by Dimitra DeFotis. Master limited partnerships (...
-
Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)
Tuesday, July 2, 2013 - 8:58am | 628Read More...Things are starting to heat up in the already hot pharmaceutical sector – especially as it relates to mergers and acquisitions. Only days after Onyx Pharmaceuticals (NASDAQ: ONXX) said it rejected an $8.7 billion buyout offer from Amgen (NASDAQ: AMGN), according to Reuters, the company has...
-
BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in November
Sunday, December 2, 2012 - 9:29pm | 617Read More...Here is a quick look at some of the top-performing health care sector stocks in the past month. These companies all have a market cap of more than $500 million, and their share prices are more than 20 percent higher than 30 days ago. BioMarin Pharmaceutical (NASDAQ: BMRN) in early November...
-
Citi Reports Uneventful 4Q For Isis Pharmaceuticals
Tuesday, March 1, 2011 - 9:08am | 70Read More...According to Citi, Isis Pharmaceuticals (NASDAQ: ISIS) had an uneventful 4Q. Citi said that ISIS reported total revenues of $26.4M, higher than our estimate of $25.1M and consensus estimate of $22.6M. “EPS for 4Q came in at ($0.14), comparing to our and Street estimates of ($0.13) and ($0.22)...
-
Cantor Fitzgerald Reiterates Isis Pharmaceuticals (ISIS) Buy Rating
Monday, March 8, 2010 - 11:45am | 136Read More...Cantor Fitzgerald analyst Pamela Bassett reiterated her Buy rating for shares of Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), with a price target of $28. Bassett noted that ISIS-SOD1Rx has been granted Orphan Drug designation by the FDA and funding from the ALS Association and the Muscular Dystrophy...
